INSIGHT-Tests for new cancer drugs not reliable enough, doctors say

CHICAGO, June 2 (Reuters) - Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said.